[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100467736":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":26,"centralContacts":31,"locations":41,"responsibleParty":59,"collaborators":25,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":64,"sex":70,"minAge":71,"maxAge":25,"enrollmentInfo":72,"targetDuration":25,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":82,"overallStatus":43,"whyStopped":25,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Corewell Health East","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Emsella Chair Active Treatment","ACTIVE_COMPARATOR","Subjects will be asked to sit on the device and the height will be adjusted until the subject's feet are on the floor. The active treatments are individualized, since some subjects will be more sensitive than others. The Emsella chair will be turned on and the setting gradually increased to the subject's sensory threshold; the maximum sensation the subject can tolerate. The setting will be decreased slightly and stay unchanged for the remainder of the treatment. The treatment threshold should be increased with every treatment until the subject reaches 100%.",[13],"Device: BTL Emsella Chair",{"label":15,"type":16,"description":17,"interventionNames":18},"Emsella Chair Sham Treatment","SHAM_COMPARATOR","Sham treatment subjects will be positioned on the device in the same manner. The sham treatment will provide some sensation without active HIFEM technology. The programming for the sham treatment will have an amplitude limitation, with the setting below the therapeutic level (\\\u003C10% power).",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DEVICE","BTL Emsella Chair","Subjects will sit on the device. The clinical research coordinator will turn the device on and increase the setting gradually until the patient reaches their sensory threshold. This is the maximum sensation the patient can tolerate. The treatment threshold should be increased until the subject reaches 100%.",[9,15],null,[27],{"name":28,"affiliation":29,"role":30},"Kenneth Peters, MD","Corewell Health William Beaumont University Hospital","PRINCIPAL_INVESTIGATOR",[32,37],{"name":33,"role":34,"phone":35,"phoneExt":25,"email":36},"Jo Medado-Ramirez, BSN","CONTACT","248-551-7360","Josephine.Medado-Ramirez@corewellhealth.org",{"name":38,"role":34,"phone":39,"phoneExt":25,"email":40},"Jennifer Giordano, BSN","248-551-3517","Jennifer.Giordano@corewellhealth.org",[42],{"facility":29,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"RECRUITING","Royal Oak","Michigan","48073","United States","US",{"type":50,"coordinates":51},"Point",[52,53],-83.14465,42.48948,{"lat":53,"lon":52},[56,57,58],{"name":33,"role":34,"phone":35,"phoneExt":25,"email":36},{"name":38,"role":34,"phone":39,"phoneExt":25,"email":40},{"name":28,"role":30,"phone":25,"phoneExt":25,"email":25},{"type":30,"investigatorFullName":60,"investigatorTitle":61,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Kenneth M Peters, MD","Director and Chair of the Department of Urology","100467736","emsella-chair-vs-sham-for-male-sexual-dysfunction-100467736",false,"NCT05370651","Emsella Chair vs Sham for Male Sexual Dysfunction","A Single-Blind, Randomized Study of the BTL Emsella Chair Versus Sham for the Treatment of Male Sexual Dysfunction","Emsella_EJD","Inclusion Criteria:\n\n1. Able to read, understand, and provide written, dated, informed consent prior to screening, and be likely to comply with study protocol, including independently complete study questionnaires and communicate with study personnel about adverse events and other clinically important information.\n2. Men ≥ 18 years of age.\n3. Sexually active within the past 12 weeks and plan to be sexually active during the next 12 weeks.\n\n5\\. Self-reported ejaculatory dysfunction symptoms present \\>3 months 6. Self-reported failed conservative care of behavioral modifications and\u002For oral medications.\n\n7\\. Subject agrees not to start any new treatment for erectile dysfunction or ejaculatory dysfunction during the treatment and follow-up periods.\n\nExclusion Criteria:\n\n1. Botox® use in bladder or pelvic floor muscles in the past year\n2. Subject weighs greater than 330 pounds, due to weight limits of the Emsella Chair.\n3. Pulmonary insufficiency, defined as difficulty breathing and fatigue, especially during exercise; chest pain, such as squeezing, pressure of tightness; the sensation of rapid or irregular heartbeat (palpitations); swelling of the legs or feet; dizziness or fainting; and\u002For bluish discoloration of the nails and\u002For lips (cyanosis)\n4. Any condition that causes a lack of normal skin sensation to the pelvis, thigh, or buttocks.\n5. Major metal implants such as: metal plates, screws, joint replacements, implanted cardiac pacemakers, drug pumps, neurostimulators, electronic implants, defibrillators, and metal implants in the pelvic area. Patients with other metal implants will be evaluated by the investigator for inclusion in the study.\n6. Previous or current penile prosthesis.\n7. Subject has a piercing between the waist and knees and is not willing to remove it before each treatment\n8. Active urethral diverticula\n9. Known history of urethral stricture disease\n10. Currently healing from surgical procedures where muscle contraction may disrupt the healing process\n11. Subject is currently receiving treatment for a malignant tumor that would interfere with study participation.\n12. Subject has used the BTL EMSELLA device previously\n13. Subject has sexual dysfunction of neurogenic etiology, such as multiple sclerosis, spina bifida, Parkinson's, spinal cord injury, diabetic neuropathy, neurogenic bladder etc.\n14. Current use of neuromodulation therapy, including Interstim and percutaneous tibial nerve stimulation (PTNS), for bladder symptoms within 3 months of screening visit (if past sacral\u002Fpudendal implant, must be explanted)\n15. Currently participating in an investigational study that may impact study results or previously received an investigational drug or treatment within 30 days of the Screening Visit\n16. Current or history of any physical condition that, in the investigator's opinion, might put the subject at risk or interfere with study results interpretation\n\n    * Note for the sake of preserving scientific integrity, one or more of the eligibility criteria have been left off the list posted while the trial is ongoing. A full list of eligibility criteria will be posted upon completion of the trial.","MALE","18 Years",{"count":73,"type":74},117,"ESTIMATED","INTERVENTIONAL",[77],"NA","We will be performing this study in 2 phases: Phase 1 will be an open label pilot study of 10 male participants. All participants in the pilot study will receive active treatment. If data from the pilot study is suggestive of symptom improvement, we will continue on to phase 2, which is a sham controlled, randomized blinded study. Participants in phase 2 will be randomized to receive either active treatment or sham. Potentially a total of 117 participants for both phases will be enrolled.\n\nThe purpose of this study is to compare the Emsella Chair to sham and to determine whether electromagnetic technology is effective in the treatment of sexual dysfunction, specifically erectile dysfunction (EjD) in men.",[80,81],"Male Sexual Dysfunction","Ejaculatory Dysfunction",[80],"2025-12-05",{"date":85,"type":86},"2025-12-11","ACTUAL",{"date":88,"type":86},"2022-12-14",{"date":90,"type":74},"2027-12",{"name":5,"class":6},1]